Assessing siRNA Pharmacodynamics in a Luciferase-expressing Mouse
Year: 2008
Type: article
Abstract: A significant barrier to the successful general development of small-interfering RNA (siRNA) therapeutics is the ability to deliver them systemically to target organs and cell types. In this study, we have developed a mouse strain that will facilitate the evaluation of the efficacy of siRNA delivery strategies. This strain contains robust ubiquitous expression of firefly luciferase from germ line Cre-mediated recombination of the ROSA26-LSL-Luc allele. We show that luciferase is highly and uniformly expressed in all tissues examined. Using this mouse model, we describe a facile assay that enables the assessment of the pharmacodynamics of a systemically delivered siRNA formulation. These mice can also be used as universal donors, enabling the efficient and sensitive monitoring of cell trafficking or tissue transplantation. The primary advantage of this approach is that siRNA efficacy against a nonessential target can be easily evaluated in any tissue. This strain should generally enhance the ability to rapidly screen, compare and optimize various siRNA formulations for tissue-targeted or -enhanced systemic delivery in a preclinical development setting.
Source: Molecular Therapy
DOI: 10.1038/mt.2008.187
Authors: Robert U Svensson, Michael R Shey, Zuhair K Ballas, J Robert Dorkin, Michael Goldberg, Akin Akinc, Robert Langer, Daniel G Anderson, David Bumcrot, Michael D Henry
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: hybrid
Estimated APC paid: $4,500
Awards: Controlled Release of Macromolecules, G1700988397, G336615015, G3421484818, KILLER CELLS AND ALCOHOL, A new high-throughput gastrointestinal tract explant platform for drug formulation discovery and metabolic disease modulation, G565511564, G5797641063, G630064964, Cancer Center Support Grant, Precision Medicine Center for Cystic Fibrosis
OpenAlex ID: W2034264394
